Alector Inc (NASDAQ:ALEC) shares saw an uptick in trading volume on Friday . 1,554,491 shares were traded during trading, an increase of 231% from the previous session’s volume of 470,256 shares.The stock last traded at $18.05 and had previously closed at $17.35.

Several research firms recently commented on ALEC. Cowen began coverage on Alector in a research note on Monday, March 4th. They set an “outperform” rating for the company. Svb Leerink assumed coverage on Alector in a research note on Monday, March 4th. They set an “outperform” rating for the company. Leerink Swann assumed coverage on Alector in a research note on Monday, March 4th. They issued an “outperform” rating for the company. Morgan Stanley assumed coverage on Alector in a research note on Monday, March 4th. They issued an “overweight” rating and a $27.00 price objective for the company. Finally, Barclays assumed coverage on Alector in a research note on Monday, March 4th. They issued an “overweight” rating and a $27.00 price objective for the company. Six equities research analysts have rated the stock with a buy rating, Alector has an average rating of “Buy” and an average price target of $26.67.

In other news, Director Orbimed Advisors Llc acquired 411,700 shares of Alector stock in a transaction on Monday, February 11th. The stock was purchased at an average price of $19.00 per share, with a total value of $7,822,300.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

ILLEGAL ACTIVITY WARNING: This article was first published by Marea Informative and is the sole property of of Marea Informative. If you are viewing this article on another site, it was illegally copied and reposted in violation of U.S. & international copyright & trademark laws. The original version of this article can be viewed at https://www.mareainformativa.com/news/2019/03/17/alector-alec-sees-strong-trading-volume.html.

Alector Company Profile (NASDAQ:ALEC)

Alector, Inc, a clinical stage biotechnology company, focuses on developing therapies that harness the immune system to cure neurodegenerative diseases. Its products in Phase I clinical trial include AL001, a humanized recombinant monoclonal antibody for the treatment of frontotemporal dementia; and AL002 for the treatment of Alzheimer's disease.

Further Reading: SEC Filing

Receive News & Ratings for Alector Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alector and related companies with MarketBeat.com's FREE daily email newsletter.